A Comprehensive Update on Nanotechnology in Functional Food Developments: Recent Updates, Challenges, and Future Perspectives.

The food business makes extensive use of lipophilic bioactive substances derived from plants, such as phytosterols, antimicrobials, antioxidants, ω3 fatty acids, tastes, and countless other constituennts. The preponderance of these bioactive substances, nevertheless, is just about unsolvable in hydric solution and unbalanced at a particular eco-friendly provocation, such as sunlight, temperature, and oxygen, in construction, transference, storage, and employment, for example, icy, chilling, desiccation, warm air dealing out, or machine-driven agitation. According to this standpoint, there are high-tech hitches that must be resolved to inform functionality for the social figure due to the lipophilic bioactive dearth of solubilization, bioavailability, and permanency. This leads to failure in commercialization and quality enhancement. Nanotechnology can generally be used to manufacture nano-kinds of stuff like nano-emulsion, nanoparticles, nanostructured materials, and nanocomposites. The creation of functional foods has attracted a huge interest as our consideration of their affiliation with nourishment and human health has grown. There are still a number of problems that need to be fixed, such as finding useful substances, figuring out ideal intake amounts, and fashioning apt food conveyance systems in addition to product compositions. In several of these areas, new methods and materials developed through nanotechnology have the potential to offer fresh explanations. The present article provides a thorough examination of nanotechnologies employed in the development of functional foods. It outlines the current patterns and forthcoming outlooks of sophisticated nanomaterials in the food industry, with particular emphasis on their applications in processing, packaging, safety, and preservation. The utilization of nanotechnologies in the food industry can improve the "bioavailability, taste, texture, and consistency of food products". This is accomplished by manipulating the particle size, potential cluster formation, and surface charge of food nanomaterials. Furthermore, this paper examines the utilization of nano-delivery systems for administering nutraceuticals, the cooperative effects of nanomaterials in safeguarding food, and the implementation of nano-sensors in intelligent food packaging to monitor the quality of stored food. Additionally, the customary techniques employed for evaluating the influence of nanomaterials on biological systems are also addressed. This review gives a general synopsis of the newfangled possibilities and hitches for systems built on nanotechnology for the creation of functional foods in the future.

Aducanumab in Alzheimer's disease: A critical update.

Alzheimer's disease (AD) is a complex neurological disorder that results in cognitive decline. The incidence rates of AD have been increasing, particularly among individuals 60 years of age or older. In June 2021, the US FDA approved aducanumab, the first humanized monoclonal antibody, as a potential therapeutic option for AD. Clinical trials have shown this drug to effectively target the accumulation of Aß (beta-amyloid) plaques in the brain, and its effectiveness is dependent on the dosage and duration of treatment. Additionally, aducanumab has been associated with improvements in cognitive function. Biogen, the pharmaceutical company responsible for developing and marketing aducanumab, has positioned it as a potential breakthrough for treating cerebral damage in AD. However, the drug has raised concerns due to its high cost, limitations, and potential side effects. AD is a progressive neurological condition that affects memory, cognitive function, and behaviour. It significantly impacts the quality of life of patients and caregivers and strains healthcare systems. Ongoing research focuses on developing disease-modifying therapies that can halt or slow down AD progression. The pathogenesis of AD involves various molecular cascades and signaling pathways. However, the formation of extracellular amyloid plaques is considered a critical mechanism driving the development and progression of the disease. Aducanumab, as a monoclonal antibody, has shown promising results in inhibiting amyloid plaque formation, which is the primary pathological feature of AD. This review explores the signaling pathways and molecular mechanisms through which aducanumab effectively prevents disease pathogenesis in AD.

Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases.

The human microbiota is fundamental to correct immune system development and balance. Dysbiosis, or microbial content alteration in the gut and respiratory tract, is associated with immune system dysfunction and lung disease development. The microbiota's influence on human health and disease is exerted through the abundance of metabolites produced by resident microorganisms, where short-chain fatty acids (SCFAs) represent the fundamental class. SCFAs are mainly produced by the gut microbiota through anaerobic fermentation of dietary fibers, and are known to influence the homeostasis, susceptibility to and outcome of many lung diseases. This article explores the microbial species found in healthy human gastrointestinal and respiratory tracts. We investigate factors contributing to dysbiosis in lung illness, and the gut-lung axis and its association with lung diseases, with a particular focus on the functions and mechanistic roles of SCFAs in these processes. The key focus of this review is a discussion of the main metabolites of the intestinal microbiota that contribute to host-pathogen interactions: SCFAs, which are formed by anaerobic fermentation. These metabolites include propionate, acetate, and butyrate, and are crucial for the preservation of immune homeostasis. Evidence suggests that SCFAs prevent infections by directly affecting host immune signaling. This review covers the various and intricate ways through which SCFAs affect the immune system's response to infections, with a focus on pulmonary diseases including chronic obstructive pulmonary diseases, asthma, lung cystic fibrosis, and tuberculosis. The findings reviewed suggest that the immunological state of the lung may be indirectly influenced by elements produced by the gut microbiota. SCFAs represent valuable potential therapeutic candidates in this context.